OBJECTIVE: High levels of microsatellite instability (MSI-H) have been associated in many studies with improved prognosis in colon cancer. Very few studies have evaluated the effect of MSI-H on rectal cancer survival. We assessed MSI-H and other genetic and epigenetic changes on survival of 990 individuals diagnosed with first primary rectal cancer. METHODS: MSI was assessed primarily by instability in the mononucleotide repeat BAT-26. The BRAF V600E mutation was assessed by TaqMan assay. The CpG island methylator phenotype (CIMP) was determined by methylation-specific PCR of CpG islands in MLH1, methylated in tumors (MINT)1, (MINT)2, (MINT)31 and CDKN2A. KRAS2 codons 12 and 13 mutations, and TP53 mutations in exons 5-8 were determined by sequencing. RESULTS: Multivariate analysis revealed that MSI-H (HRR 2.47, 95% CI 1.13-5.40) and KRAS2 mutations (HRR 1.37, 95% CI 1.04-1.81) were associated with a significantly higher risk of dying of rectal cancer. Only one of 22 MSI-H tumors showed a BRAF V600E mutation. Of 15 MSI-H rectal cancers evaluated for methylation, two exhibited MLH1 methylation and four exhibited CIMP. CONCLUSION: The genetic and epigenetic characteristics of MSI-H rectal cancers suggest that they are enriched for Lynch-associated tumors; adverse prognosis associated with MSI-H in these tumors may reflect the relatively high frequency of Lynch-associated cancers and/or the effect of radiation or chemotherapy on Lynch-associated rectal cancers or MSI tumors in general.
OBJECTIVE: High levels of microsatellite instability (MSI-H) have been associated in many studies with improved prognosis in colon cancer. Very few studies have evaluated the effect of MSI-H on rectal cancer survival. We assessed MSI-H and other genetic and epigenetic changes on survival of 990 individuals diagnosed with first primary rectal cancer. METHODS:MSI was assessed primarily by instability in the mononucleotide repeat BAT-26. The BRAFV600E mutation was assessed by TaqMan assay. The CpG island methylator phenotype (CIMP) was determined by methylation-specific PCR of CpG islands in MLH1, methylated in tumors (MINT)1, (MINT)2, (MINT)31 and CDKN2A. KRAS2 codons 12 and 13 mutations, and TP53 mutations in exons 5-8 were determined by sequencing. RESULTS: Multivariate analysis revealed that MSI-H (HRR 2.47, 95% CI 1.13-5.40) and KRAS2 mutations (HRR 1.37, 95% CI 1.04-1.81) were associated with a significantly higher risk of dying of rectal cancer. Only one of 22 MSI-H tumors showed a BRAFV600E mutation. Of 15 MSI-H rectal cancers evaluated for methylation, two exhibited MLH1 methylation and four exhibited CIMP. CONCLUSION: The genetic and epigenetic characteristics of MSI-H rectal cancers suggest that they are enriched for Lynch-associated tumors; adverse prognosis associated with MSI-H in these tumors may reflect the relatively high frequency of Lynch-associated cancers and/or the effect of radiation or chemotherapy on Lynch-associated rectal cancers or MSI tumors in general.
Authors: W S Samowitz; K Curtin; D Schaffer; M Robertson; M Leppert; M L Slattery Journal: Cancer Epidemiol Biomarkers Prev Date: 2000-11 Impact factor: 4.254
Authors: W S Samowitz; J A Holden; K Curtin; S L Edwards; A R Walker; H A Lin; M A Robertson; M F Nichols; K M Gruenthal; B J Lynch; M F Leppert; M L Slattery Journal: Am J Pathol Date: 2001-04 Impact factor: 4.307
Authors: Wade S Samowitz; Karen Curtin; Khe-ni Ma; Sandra Edwards; Donna Schaffer; Mark F Leppert; Martha L Slattery Journal: Int J Cancer Date: 2002-06-01 Impact factor: 7.396
Authors: W S Samowitz; K Curtin; K N Ma; D Schaffer; L W Coleman; M Leppert; M L Slattery Journal: Cancer Epidemiol Biomarkers Prev Date: 2001-09 Impact factor: 4.254
Authors: Christine M Ribic; Daniel J Sargent; Malcolm J Moore; Stephen N Thibodeau; Amy J French; Richard M Goldberg; Stanley R Hamilton; Pierre Laurent-Puig; Robert Gryfe; Lois E Shepherd; Dongsheng Tu; Mark Redston; Steven Gallinger Journal: N Engl J Med Date: 2003-07-17 Impact factor: 91.245
Authors: John M Carethers; E Julieta Smith; Cynthia A Behling; Lanchinh Nguyen; Akihiro Tajima; Ryan T Doctolero; Betty L Cabrera; Ajay Goel; Christian A Arnold; Katsumi Miyai; C Richard Boland Journal: Gastroenterology Date: 2004-02 Impact factor: 22.682
Authors: R A Lothe; P Peltomäki; G I Meling; L A Aaltonen; M Nyström-Lahti; L Pylkkänen; K Heimdal; T I Andersen; P Møller; T O Rognum Journal: Cancer Res Date: 1993-12-15 Impact factor: 12.701
Authors: M Colombino; A Cossu; A Manca; M F Dedola; M Giordano; F Scintu; A Curci; A Avallone; G Comella; M Amoruso; A Margari; G M Bonomo; M Castriota; F Tanda; G Palmieri Journal: Ann Oncol Date: 2002-09 Impact factor: 32.976
Authors: Nicole de Rosa; Miguel A Rodriguez-Bigas; George J Chang; Jula Veerapong; Ester Borras; Sunil Krishnan; Brian Bednarski; Craig A Messick; John M Skibber; Barry W Feig; Patrick M Lynch; Eduardo Vilar; Y Nancy You Journal: J Clin Oncol Date: 2016-07-18 Impact factor: 44.544
Authors: V V Ravi Kanth; Sandeep Bhalsing; M Sasikala; G V Rao; R Pradeep; Urmila Steffie Avanthi; D Nageshwar Reddy Journal: Tumour Biol Date: 2014-01-10
Authors: Y Y Juo; F M Johnston; D Y Zhang; H H Juo; H Wang; E P Pappou; T Yu; H Easwaran; S Baylin; M van Engeland; N Ahuja Journal: Ann Oncol Date: 2014-04-08 Impact factor: 32.976
Authors: Marianne Berg; Stine A Danielsen; Terje Ahlquist; Marianne A Merok; Trude H Ågesen; Morten H Vatn; Tom Mala; Ole H Sjo; Arne Bakka; Ingvild Moberg; Torunn Fetveit; Øystein Mathisen; Anders Husby; Oddvar Sandvik; Arild Nesbakken; Espen Thiis-Evensen; Ragnhild A Lothe Journal: PLoS One Date: 2010-11-12 Impact factor: 3.240
Authors: Karen Curtin; Wade S Samowitz; Roger K Wolff; Jennifer Herrick; Bette J Caan; Martha L Slattery Journal: Int J Cancer Date: 2009-07-01 Impact factor: 7.396
Authors: Allison M Cushman-Vokoun; Daniel G Stover; Zhiguo Zhao; Elizabeth A Koehler; Jordan D Berlin; Cindy L Vnencak-Jones Journal: Clin Colorectal Cancer Date: 2013-06-14 Impact factor: 4.481